摘要
目的研究乌司他丁联合血液净化治疗重症感染性休克的临床效果。方法在接收并治疗的重症感染性休克患者中抽取经常规血液净化治疗的39例患者为对照组,另外抽取经乌司他丁联合血液净化治疗的41例患者为观察组。比较两组患者的炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、降钙素原(PCT)、C反应蛋白(CRP)]水平,并发症发生率。结果治疗前,两组患者的TNF-α、IL-6、PCT、CRP水平比较,差异无统计学意义(P>0.05);治疗后,观察组患者的TNF-α(8.68±1.70)ng/L、IL-6(33.11±6.47)ng/L、PCT(4.28±0.84)ng/L、CRP(25.52±4.99)mg/L均低于对照组的(14.52±2.77)ng/L、(47.11±8.97)ng/L、(6.34±1.21)ng/L、(30.06±5.72)mg/L,差异具有统计学意义(P<0.05)。观察组的并发症发生率7.32%低于对照组的35.90%,差异具有统计学意义(P<0.05)。结论通过乌司他丁联合血液净化对重症感染性休克治疗可有效降低患者的炎症因子水平,减少并发症发生率,有助于患者的疾病恢复,值得推荐。
Objective To study the clinical effect of ulinastatin combined with blood purification in the treatment of severe septic shock.Methods Among the patients with severe septic shock,39 patients treated with conventional blood purification were selected as the control group,and another 41 patients treated with ulinastatin combined with blood purification were selected as the observation group.The levels of inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),procalcitonin(PCT),and C-reactive protein(CRP)]and the incidence of complications in the two groups were compared.Results Before treatment,there were no statistically significant differences between the two groups in terms of TNF-α,IL-6,PCT and CRP(P>0.05).After treatment,the observation group had TNF-αof(8.68±1.70)ng/L,IL-6 of(33.11±6.47)ng/L,PCT of(4.28±0.84)ng/L,and CRP of(25.52±4.99)mg/L,which were lower than those of(14.52±2.77)ng/L,(47.11±8.97)ng/L,(6.34±1.21)ng/L,and(30.06±5.72)mg/L in the control group,and the differences were statistically significant(P<0.05).The incidence of complications of 7.32%in the observation group was lower than that of 35.90%in the control group,and the difference was statistically significant(P<0.05).Conclusion Ulinastatin combined with blood purification for the treatment of severe septic shock can effectively improve the level of inflammatory factors in patients,reduce the incidence of complications,and contribute to the recovery of patients'disease,which is worthy of recommendation.
作者
安丽丽
AN Li-li(Central Hospital of Yingkou Economic and Technological Development Zone(Sixth People's Hospital of Yingkou),Yingkou 115007,China)
出处
《中国现代药物应用》
2023年第14期134-136,共3页
Chinese Journal of Modern Drug Application
关键词
乌司他丁
血液净化
重症感染性休克
炎症因子
并发症
Ulinastatin
Blood purification
Severe septic shock
Inflammatory factors
Complications
